LANNETT COMP (AM:LCI)
4.55
0.4 (8.08%)
| LANNETT COMP (AM:LCI) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $4.95 | 52 Week High | $9.74 | ||
| Open | $5.00 | 52 Week Low | $4.40 | ||
| Day High | $5.00 | P/E | 14.22 | ||
| Day Low | $4.10 | EPS | $0.32 | ||
| Volume | 54,176 | ||||
| More LCI Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| SOLR | 2 | SUFB | 1 |
| CFS | 1 | ETP | 1 |
| KEYN | 1 | PIKE | 1 |
| TKTM | 1 | API | 1 |
| CPST | 1 | GIB | 1 |
| MLR | 1 | RURL | 1 |
Entities who have mentioned LCI
- KeyBanc | View Related Stories »
- Wilbur Ross | View Related Stories »
- The Carlyle Group | View Related Stories »
- Dividend | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- S3 | View Related Stories »
- HSBC | View Related Stories »
- Trading Radar | View Related Stories »
- Life, Style and Real Estate | View Related Stories »
- Stock Buyback | View Related Stories »
- Roth Capital | View Related Stories »
- UBS | View Related Stories »
View All Major News StreetInsider.com Major News for LCI
- Lannett (LCI) reports Breakeven Q2 Earnings, Misses by 4c
- Lannett (LCI) Reports Q1 EPS of $0.11, Beats by 4c
- Lannett (LCI) Tops Q4 Views
View All ReportsStreetInsider.com Reports on LCI
- Lannett (LCI) reports Breakeven Q2 Earnings, Misses by 4c
- Lannett Co. (LCI) to Submit NDA to U.S. FDA for Morphine Sulfate Products
- Lannett (LCI) Receives FDA Approval for Generic Dilaudid
- Roth Capital Resumes Coverage on Lannett (LCI) with a Buy
- Lannett (LCI) Reauthorizes $5M Buyback
View All Press ReleasesCompany Press Releases on LCI
- Lannett Reports Fiscal 2010 Second-Quarter Financial Results
- Lannett Company to Report Fiscal 2010 Second-Quarter Financial Results and Host Conference Call on Monday, February 8
- Lannett to Submit New Drug Application for Morphine Sulfate Products
StreetInsider Reports on LCI by Category
View All BlogsBlogs on LCI
- Big Lineup of Healthcare Stocks Crack the Russell 3000 Index
- 20 Bullish Stocks, 2 Detailed Trades
- Caraco Pharma Poised for a Turnaround
- Biotech Going Generic Like Big Pharma?
Comments on LCI
No comments are currently available.
